Fintel reports that on February 20, 2024, HC Wainwright & Co. initiated coverage of Dyne Therapeutics (NasdaqGS:DYN) with a Buy recommendation.
Analyst Price Forecast Suggests 55.83% Upside
As of January 19, 2024, the average one-year price target for Dyne Therapeutics is 35.70. The forecasts range from a low of 20.20 to a high of $58.80. The average price target represents an increase of 55.83% from its latest reported closing price of 22.91.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Dyne Therapeutics is 0MM. The projected annual non-GAAP EPS is -3.32.
What is the Fund Sentiment?
There are 1 funds or institutions reporting positions in Dyne Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to DYN is 0.00%, a decrease of 8.77%. Total shares owned by institutions decreased in the last three months by 0.00% to 0K shares. 
The put/call ratio of DYN is 1.46, indicating a bearish outlook.
What are Other Shareholders Doing?
Atlas Venture Life Science Advisors holds 9,885K shares representing 12.19% ownership of the company. No change in the last quarter.
Mpm Asset Management holds 4,951K shares representing 6.10% ownership of the company. No change in the last quarter.
Citadel Advisors holds 3,053K shares representing 3.76% ownership of the company. In it's prior filing, the firm reported owning 3,042K shares, representing an increase of 0.39%. The firm increased its portfolio allocation in DYN by 21.43% over the last quarter.
VR Adviser holds 2,174K shares representing 2.68% ownership of the company. No change in the last quarter.
Vida Ventures Advisors holds 2,075K shares representing 2.56% ownership of the company. In it's prior filing, the firm reported owning 2,220K shares, representing a decrease of 7.00%. The firm increased its portfolio allocation in DYN by 6.70% over the last quarter.
Dyne Therapeutics Background Information
(This description is provided by the company.)
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
